Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Way to Prevent Heart Disease in Type 1 Diabetes

By Newcastle University | October 23, 2018

Scientists reveal the mechanism which allows a commonly prescribed drug for Type 2 diabetes to prevent heart disease in patients with Type 1 diabetes –and could lead to new treatments.

Metformin is an inexpensive treatment that is often used for Type 2 diabetes to lower blood sugar levels by reducing glucose production in the liver. The drug is not regularly given to patients with Type 1 diabetes.

A clinical trial has revealed metformin can promote a patient’s ability to repair their own damaged blood vessels by decreasing the presence of microRNAs (miRs) which increases the growth of blood vessels  –  in addition to improving glucose levels.

These microRNAs are messenger molecules which with regulate different genes in different cells.

Dr Jolanta Weaver, Senior Lecturer in Diabetes Medicine at Newcastle University and Honorary Consultant Diabetologist at Queen Elizabeth Hospital, Gateshead, led the clinical trial at the Gateshead hospital and is lead author of the work published in the International Journal of Molecular Sciences. She said: “This is an exciting development as understanding this underlying mechanism opens up the possibility of new forms of treatment which will lower the chances of patients with Type 1 diabetes developing heart disease.

“As the outcomes of heart disease are worse in diabetic patients compared to people who don’t have diabetes, there is a need to identify additional treatment options.

“Our previous study showed that the vascular stem cells were improved by metformin so this was the first example how metformin improved heart disease as well as lowering glucose levels.

“Now we know that the drug metformin was able to do this by lowering the presence of microRNAs.”

A previous study revealed the potential of metformin to slow the development or delay heart disease however, this is the first time that the potential of miRs in preventing heart disease have been identified.

Clinical Trial
The study – known as MERIT  – was the first to test metformin for the cardioprotective effects in Type 1 diabetes patients. In an open label, case-controlled study, the treatment group consisted of 23 people, aged between 19 and 65, with Type 1 diabetes who were free of cardiovascular disease. They were treated with metformin for 8 weeks.

Patients in the treatment group were matched with a standard group of nine Type 1 diabetic patients taking standard insulin. Additionally, there were 23 participants in the “healthy” control group without diabetes.

At the start of the study, the anti-angiogenic microRNAs, miR-222, miR-195, and miR-21a were detected to be higher in type 1 diabetic patients compared to the control group. However, metformin treatment successfully reduced the levels of miR-222, miR-195, and miR-21a. 

Moreover, as the levels of miR-222 lowered, there was a corresponding decrease in the amount of circulating endothelial cells, which indicates an improvement in vascular repair.

Weaver adds: “These results confirm that as well as improving a patient’s blood sugar control, metformin is working to protect the heart.”

The team will now be working to further the work with the goal of developing new therapies based on regulating the levels of microRNAs.

This work was funded by the Diabetes Research and Wellness Foundation and the Diabetes Research Fund at the Queen Elizabeth Hospital, Gateshead.

SOURCE: Newcastle University


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE